XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.
Total raised: $58.9M
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 22.03.2021 | Series A | $41.9M | - | fh-partner... |
| 06.12.2018 | Series A | $17M | - | medcitynew... |
Mentions in press and media 22
| Date | Title | Description | Source |
| 25.08.2023 | XyloCor Therapeutics Presents Phase 2 Data Highlighting Sa... | Positive Phase 2 EXACT Trial results at 6-months underscore significant potential of investigational... | fh-partner... |
| 03.08.2023 | Results from XyloCor Therapeutics’ Phase 1 Portion of EXAC... | Findings from the Phase 1 dose escalation portion of the EXACT trial of XC001 in refractory angina p... | fh-partner... |
| 18.07.2023 | XyloCor Therapeutics Reports Sustained Results in 12- Mont... | XC001 demonstrated durable improvements across multiple efficacy measures 12 months after treatment,... | fh-partner... |
| 26.01.2023 | XyloCor Therapeutics Reports Positive Topline Safety and Eff... | No serious adverse events related to drug product were reported Patients demonstrated improvements i... | lumiravent... |
| 26.01.2023 | XyloCor Therapeutics Reports Positive Topline Safety and E... | No serious adverse events related to drug product were reported Patients demonstrated improvements ... | fh-partner... |
| 28.06.2022 | XyloCor Therapeutics Achieves Target Enrollment in Phase 2 E... | XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for... | lumiravent... |
| 28.06.2022 | XyloCor Therapeutics Achieves Target Enrollment in Phase 2... | XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies f... | fh-partner... |
| 18.05.2022 | XyloCor Therapeutics Announces Presentation of Preliminary... | XyloCor Therapeutics, a clinical‑stage biopharmaceutical company developing novel gene therapies f... | fh-partner... |
| 18.01.2022 | XyloCor Therapeutics Expands Leadership Team with Accompli... | XyloCor Therapeutics, a clinical‑stage biopharmaceutical company developing novel gene therapies f... | fh-partner... |
| 27.07.2021 | XyloCor Therapeutics Commences Phase 2 Component of Phase 1/... | Wayne, PA, July 27, 2021 – XyloCor Therapeutics, a clinical-stage biopharmaceutical company developi... | lumiravent... |
Show more